Given the diverse biological behaviors and therapeutic challenges associated with HER2-positive and ER+/PR+ breast cancers, a deeper understanding of their molecular mechanisms is essential for advancing personalized treatment approaches and improving patient outcomes. This evidence concerns the gene ESR1 and breast carcinoma.